Findings

What do systematic reviews say?

11 questions · 11 findings · 2 reviews · Injuries

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 27.3%GRADE not reported 0 · 0%Very low 7 · 63.6%Low 1 · 9.1%Moderate 0 · 0%High 0 · 0%

Intravenous tranexamic acid vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
Peto OR 0.38 [0.05, 2.77]
2 studies · 147 participants
Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
RD 0
1 study · 36 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · cancer surgery

It is very uncertain whether cell salvage changes mortality (up to 90 days) compared with no cell salvage (very low certainty).

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
RR 0.56 [0.11, 2.8]
2 studies · 79 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · cardiovascular (vascular) surgeries

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
1.19 [0.39, 3.65]
6 studies · 384 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · cardiovascular (no bypass) surgeries

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
0.13 [0.01, 2.07]
4 studies · 209 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · cardiovascular (with bypass) surgeries

It is very uncertain whether cell salvage changes mortality (up to 90 days) compared with no cell salvage (very low certainty).

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
RR 0.86 [0.5, 1.48]
21 studies · 2491 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · orthopaedic (hip)

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
0.46 [0.06, 3.33]
4 studies · 651 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) · orthopaedic (mixed)

It is very uncertain whether cell salvage changes mortality (up to 90 days) compared with no cell salvage (very low certainty).

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
RD 0
1 study · 69 participants
Very low

Cell salvage vs no cell salvage

Mortality (up to 90 days) ‐ not reported · obstetric surgeries

The review found no eligible studies for this question.

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cell salvage vs no cell salvage

Mortality (up to 90 days) ‐ not reported · orthopaedic (knee)

The review found no eligible studies for this question.

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cell salvage vs no cell salvage

Mortality (up to 90 days) ‐ not reported · orthopaedic (spinal)

The review found no eligible studies for this question.

1 finding from 1 review

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found